 Drugbiotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly LLY, Novo Nordisk NVO, Merck MRK and Glaxo GSK are worth retaining in your portfolio. 